Abbott Laboratories (ABT) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to $1.6 billion.
- Abbott Laboratories' Income from Continuing Operations fell 12.15% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $14.0 billion, marking a year-over-year increase of 14236.17%. This contributed to the annual value of $13.4 billion for FY2024, which is 13417.79% up from last year.
- As of Q3 2025, Abbott Laboratories' Income from Continuing Operations stood at $1.6 billion, which was down 12.15% from $1.8 billion recorded in Q2 2025.
- In the past 5 years, Abbott Laboratories' Income from Continuing Operations ranged from a high of $9.2 billion in Q4 2024 and a low of $1.0 billion during Q4 2022
- Over the past 5 years, Abbott Laboratories' median Income from Continuing Operations value was $1.6 billion (recorded in 2023), while the average stood at $2.0 billion.
- As far as peak fluctuations go, Abbott Laboratories' Income from Continuing Operations plummeted by 4806.44% in 2022, and later surged by 47898.37% in 2024.
- Quarter analysis of 5 years shows Abbott Laboratories' Income from Continuing Operations stood at $2.0 billion in 2021, then tumbled by 48.06% to $1.0 billion in 2022, then soared by 54.31% to $1.6 billion in 2023, then soared by 478.98% to $9.2 billion in 2024, then tumbled by 82.19% to $1.6 billion in 2025.
- Its Income from Continuing Operations stands at $1.6 billion for Q3 2025, versus $1.8 billion for Q2 2025 and $1.3 billion for Q1 2025.